Clinical Trial · NCT03857087

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

Overview

This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.

Sponsor

University of California, San Francisco

Contacts

Michael Ohliger, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03857087

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Linker: Ahx

Eligibility

Inclusion

Female,
Creatinine \</= 1.5 mg/dL
Patients with one of the following, identified on prior imaging (CT, MRI or Ultrasound):
adnexal mass
abdominal or pelvic tumor suspicious for ovarian cancer metastases (either suspected on clinical grounds, or known from prior tissue sampling)

Exclusion

Exclusion criteria not yet provided.